,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'mbc']
#asco2022 modi plenary talk on trastuzumab deruxtecan for her2-low mbcl. phase. 3 trial randomized her2-low pts to t-dxd or treatment of physicians choice. tpc options include cape, eribilin, gem, paclitaxel or nab-pac with pfs as primary endpoint and os secondary.
Professor of Medicine, Stanford University; breast cancer doc